Premium
Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant
Author(s) -
Foster Jennifer H.,
Cheng W. Susan,
Nguyen NgocYen,
Krance Robert,
Martinez Caridad
Publication year - 2018
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13141
Subject(s) - cidofovir , hemorrhagic cystitis , medicine , bk virus , hematopoietic stem cell transplantation , toxicity , complication , hematopoietic stem cell , pharmacology , gastroenterology , stem cell , anesthesia , transplantation , virus , haematopoiesis , immunology , kidney transplantation , biology , genetics
BK virus hemorrhagic cystitis is a complication of HCST . Response to IV cidofovir is unpredictable, and treatment carries risk of toxicity. We report the largest series of pediatric patients with BKHC after HSCT successfully treated with intravesicular cidofovir. There was no significant decrease in urine or plasma BK PCR . There was significant decrease in pain score on days 3 and 7, with associated decrease in morphine use. No patients experienced toxicities associated with IV cidofovir. Intravesicular cidofovir appears to be safe and effective for symptomatic treatment of BKHC in pediatric patients after HSCT .